Affiliation:
1. From the Montreal Heart Institute and Université de Montreal, Montreal (N.F.-S., F.L., M.T., P.K., E.O., D.R.); St Michael's Hospital, Toronto (P.D.); Centre Hospitalier de l'Université de Montréal, Montreal (N.F.-S., F.L.); and McGill University, Montreal, Canada (N.F.-S., F.L.).
Abstract
Background—
Patients with high anxiety sensitivity (AS) become extremely anxious with heart rate increases, palpitations, and symptoms of psychological arousal. AS predicts panic attacks. In atrial fibrillation (AF), AS correlates with symptom preoccupation and reduced quality of life. We assessed whether AS is associated with outcomes of rhythm-control versus rate-control in congestive heart failure (CHF) patients with AF.
Methods and Results—
Before random assignment, 933 participants (172 women) in the Atrial Fibrillation and Congestive Heart Failure Trial completed the Anxiety Sensitivity Inventory (ASI). Cox proportional hazards models showed no main effects of treatment (
P
=0.61) or AS (
P
=0.72) for time to cardiovascular death, but these factors interacted significantly (
P
=0.020). High AS patients (upper quartile, ASI ≥33) randomly assigned to rhythm-control had significantly lower cardiovascular mortality than those receiving rate-control (hazard ratio, 0.54; 95% confidence interval, 0.32–0.93;
P
=0.022). With lower ASI scores (<33), treatments did not differ (hazard ratio, 1.12; 95% confidence interval, 0.83–1.51;
P
=0.46). The interaction between treatment and dichotomized ASI scores remained significant (
P
=0.009) after adjustment for covariates including age, sex, hypertension, diabetes, creatinine, ejection fraction, time since first diagnosis of AF, New York Heart Association functional class, depression symptoms, marital status, and baseline β-blockers, angiotensin-converting enzyme inhibitors, oral anticoagulants, and implantable cardioverter-defibrillators.
Conclusions—
Atrial fibrillation and congestive heart failure patients with high AS had better long-term prognosis with rhythm- than rate-control. If replicated, AS should be considered in treatment selection. Research is also needed concerning mechanisms and possible joint AS-AF treatments.
Clinical Trial Registration—
URL:
http://www.clinicaltrials.gov
. Unique identifier: NCT88597077.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献